The therapeutic potential of natural metabolites in targeting endocrine-independent HER-2-negative breast cancer DOI Creative Commons
Mirosława Püsküllüoğlu, Izabela Michalak

Frontiers in Pharmacology, Год журнала: 2024, Номер 15

Опубликована: Март 4, 2024

Breast cancer (BC) is a heterogenous disease, with prognosis and treatment options depending on Estrogen, Progesterone receptor, Human Epidermal Growth Factor Receptor-2 (HER-2) status. HER-2 negative, endocrine-independent BC presents significant clinical challenge limited options. To date, promising strategies like immune checkpoint inhibitors have not yielded breakthroughs in patient prognosis. Despite being considered archaic, agents derived from natural sources, mainly plants, remain backbone of current treatment. In this context, we critically analyze novel naturally-derived drug candidates, elucidate their intricate mechanisms action, evaluate pre-clinical vitro vivo activity negative BC. Since research success often does directly correlate approval, focus ongoing trials to uncover trends. Finally, demonstrate the potential combining cutting-edge technologies, such as antibody-drug conjugates or nanomedicine, agents, offering new opportunities that utilize both traditional cytotoxic metabolites.

Язык: Английский

New Achievements for the Treatment of Triple-Negative Breast Cancer DOI Creative Commons
Alessia Catalano, Domenico Iacopetta, Jessica Ceramella

и другие.

Applied Sciences, Год журнала: 2022, Номер 12(11), С. 5554 - 5554

Опубликована: Май 30, 2022

Triple-negative breast cancer (TNBC) constitutes a heterogeneous group of malignancies that are often aggressive and associated with poor prognosis. The development new TNBC treatment strategies has become an urgent clinical need. Diagnosis subtyping essential to establish alternative treatments targeted therapies for every patient. Chemotherapy, particularly anthracycline taxanes, remains the backbone medical management both early metastatic TNBC. More recently, immune checkpoint inhibitors therapy have revolutionized treatment. Included in different studied is drug repurposing. Despite numerous medications available, studies medicinal chemistry still aimed at synthesis compounds order find antiproliferative agents capable treating Additionally, some supplemental micronutrients, nutraceuticals functional foods can potentially reduce risk developing or retard rate growth metastases established malignant diseases. Finally, nanotechnology medicine, termed nanomedicines, introduces nanoparticles variable architecture This review highlights most recent search TNBC, along repositioning drugs.

Язык: Английский

Процитировано

24
Signaling Pathways and Natural Compounds in Triple-Negative Breast Cancer Cell Line DOI Creative Commons
Citra Dewi, Adryan Fristiohady, Riezki Amalia

и другие.

Molecules, Год журнала: 2022, Номер 27(12), С. 3661 - 3661

Опубликована: Июнь 7, 2022

Triple-negative breast cancer (TNBC) is the most aggressive subtype of cancer, having a poor prognosis and rapid metastases. TNBC characterized by absence estrogen, progesterone, human epidermal growth receptor-2 (HER2) expressions has five-year survival rate. Compared to other subtypes, patients only respond conventional chemotherapies, even then, with limited success. Shortages chemotherapeutic medication can lead resistance, pressured index therapy, non-selectivity, severe adverse effects. Finding targeted treatments for difficult owing various features cancer. Hence, identifying effective molecular targets in pathogenesis essential predicting response therapies preventing cell Nowadays, natural compounds have gained attention as treatments, offered new strategies solving drug resistance. Here, we report systematic review using database from Pubmed, Science Direct, MDPI, BioScince, Springer, Nature articles screening 2003 2022. This analyzes relevant signaling pathways prospect utilizing therapeutic agent improve future.

Язык: Английский

Процитировано

23
Nanoparticulate drugs and vaccines: Breakthroughs and bottlenecks of repurposing in breast cancer DOI
Popat Kumbhar,

Kapil Kole,

Varsha Khadake

и другие.

Journal of Controlled Release, Год журнала: 2022, Номер 349, С. 812 - 830

Опубликована: Авг. 3, 2022

Язык: Английский

Процитировано

22
Finding New Molecular Targets of Two Copper(II)-Hydrazone Complexes on Triple-Negative Breast Cancer Cells Using Mass-Spectrometry-Based Quantitative Proteomics DOI Open Access
Lucía M. Balsa, María R. Rodríguez,

Verónica Ferraresi-Curotto

и другие.

International Journal of Molecular Sciences, Год журнала: 2023, Номер 24(8), С. 7531 - 7531

Опубликована: Апрель 19, 2023

Breast cancer is the most common in women, with a high incidence estimated to reach 2.3 million by 2030. Triple-Negative Cancer (TNBC) greatest invasive class of breast poor prognosis, due side-effects exerted chemotherapy used and low effectivity novel treatments. In this sense, copper compounds have shown be potentially effective as antitumor agents, attracting increasing interest alternatives usually employed platinum-derived drugs. Therefore, aim work identify differentially expressed proteins MDA-MB-231 cells exposed two copper(II)-hydrazone complexes using label-free quantitative proteomics functional bioinformatics strategies molecular mechanisms through which these exert their antitumoral effect TNBC cells. Both increased involved endoplasmic reticulum stress unfolded protein response, well downregulation related DNA replication repair. One relevant anticancer action found for CuHL1 CuHL2 was down-regulation gain-of-function-mutant p53. Moreover, we interesting metallodrug, lipid synthesis metabolism that could lead beneficial decrease levels.

Язык: Английский

Процитировано

13
Resveratrol contributes to NK cell-mediated breast cancer cytotoxicity by upregulating ULBP2 through miR-17-5p downmodulation and activation of MINK1/JNK/c-Jun signaling DOI Creative Commons

Bisha Ding,

Jie Li,

Jia-Lin Yan

и другие.

Frontiers in Immunology, Год журнала: 2025, Номер 16

Опубликована: Фев. 3, 2025

Backgrounds Natural killer (NK) cell mediated cytotoxicity is a crucial form of anti-cancer immune response. group 2 member D (NKG2D) prominent activating receptor NK cell. UL16-binding protein (ULBP2), always expressed or elevated on cancer cells, functions as key NKG2D ligand. ULBP2-NKG2D ligation initiates activation and subsequent targeted elimination cells. Enhanced expression ULBP2 cells leads to more efficient these by Resveratrol (RES) known for its multiple health benefits, while current understanding role in regulating immunogenicity remains limited. This study aims investigate how RES affects the sensitivity breast (BC) cytotoxicity, along with underlying mechanisms. Methods The effects were detected qRT-PCR, western blot, flow cytometry analysis immunohistochemistry. BC evaluated vitro vivo . target gene miR-17-5p predicted different algorithms from five databases further confirmed dual-luciferase reporter assay. Overexpression knockdown experiments MINK1 conducted their roles JNK/c-Jun activation. JNK inhibitor sp600125 was utilized elucidate specific modulating expression. Results increased thereby augmenting vulnerability cell-mediated both administration led reduction cellular level. MiR-17-5p negatively regulated Specifically, directly MINK1, leading suppression. played facilitating downstream effector, c-Jun. Furthermore, treatment sp600125, inhibitor, resulted suppression Conclusions： potentiates ULBP2-mediated eradication through downregulation concurrent MINK1/JNK/c-Jun cascade. finding identifies potentially effective therapeutic agent inhibiting progression optimizing cell-based immunotherapy.

Язык: Английский

Процитировано

0
Breaking Barriers; Phytoestrogens in the Fight Against Triple‐Negative Breast Cancer: A Comprehensive Review DOI Open Access
Md Sohel

Medicinal Research Reviews, Год журнала: 2025, Номер unknown

Опубликована: Март 12, 2025

ABSTRACT The development of standard drugs for some unusual cancers, including estrogen‐nonresponsive breast cancer, is somewhat difficult within a very short time. So, considering the current situation, phytoestrogen may be potential candidate unraveling chemotherapeutics agents. reason this review article to manifest overall information regarding effects on triple‐negative cancer (TNBC), along with its related cellular and molecular pathways in different TNBC models. Data was retrieved by systematic searches according PRISMA guidelines, commonly used tools servers are BioRender, ChemDraw professional 16.0, Schrodinger, ADMETlab 2.0. caused due dysregulation several signaling mechanisms such as Wnt/β‐catenin, hedgehog, MAPK, notch, PI3K/AKT/mTOR, hippo, NF‐κB, JAK/STAT cascades. Among all phytoestrogens ( n = 150), 48 compounds therapeutically effective vitro preclinical Chemotherapeutics activities regulated through varieties mechanisms, targeting phosphor‐Akt, TNF‐α; apoptosis FASL, Bcl2, Bax, Bak, Bad, apfa1, ASK1, Capase, PARP; metastasis MMPs (1,2,3,9), Wnt/‐β catenin, angiogenesis (E&N Cadherin, Vimentin), cell proliferation (cyclins‐A, B1, D1, E1, CDKs 1, 6,7), inflammatory molecules (TNF‐α, IL‐1β, IL‐8), regulating tumor suppressor genes (p21, p27, p51, p53) nonspecific like DNA damage repair (γH2AX, RAD51, surviving), autophagy (mTOR, ULK1, cathepsin B), epigenetic (HDAC1, DNMT1, telomerase production) metabolism regulation (glucose regulation‐GLUT1 GLUT4), showing antioxidant many other pathways. Some selective exert synergistic conventional well radiotherapy mechanism reverse drug resistance EMT process, pathways, sensitizing, miRNA regulation, improving uptake. Nano‐based can target cells, stimulate accumulation, improve efficacies, making more agents treating TNBC. Additionally, an in‐silico pharmacokinetics study reveals that possesses suitable pharmacokinetic characteristics minor toxicity. against until fully pharma available at markets.

Язык: Английский

Процитировано

0
Synergic anti-tumor effects of photodynamic therapy and resveratrol on triple-negative breast cancer cells DOI
Mohammad Ghazizadeh, Khatereh Khorsandi,

SMahmoud A. Najafi

и другие.

Photochemical & Photobiological Sciences, Год журнала: 2025, Номер unknown

Опубликована: Март 17, 2025

Язык: Английский

Процитировано

0
An extensive analysis of the biochemical dimensions of phytochemicals in the treatment or prevention of breast cancer DOI
Monika Kumari, Kapil Vashisht, Manoj Kumar

и другие.

Phytochemistry Reviews, Год журнала: 2025, Номер unknown

Опубликована: Апрель 8, 2025

Язык: Английский

Процитировано

0
Antigenotoxic and antitumor properties of polyphenols DOI
Vipendra Kumar Singh, Vikas Kumar Singh,

Arjun Kumar Mehara

и другие.

Elsevier eBooks, Год журнала: 2025, Номер unknown, С. 251 - 282

Опубликована: Янв. 1, 2025

Язык: Английский

Процитировано

0
Effect of Natural Polyphenols on Breast Cancer Chemoprevention and Treatment DOI Creative Commons
Marzia Sichetti,

Martina Giuseffi,

Eugenia Giglio

и другие.

Molecular Nutrition & Food Research, Год журнала: 2025, Номер unknown

Опубликована: Апрель 7, 2025

ABSTRACT Breast cancer is the most common type of malignancy among women worldwide. Significant achievements have been made in diagnostic tools and treatments past decade; however, complexity heterogeneity certain breast subtypes often lead to drug resistance metastatic progression. Owing their low toxicity high variety, natural products derivatives are becoming increasingly valuable sources for small‐molecule anticancer drugs. Polyphenols more widely known role prevention as adjuvants conventional treatment strategies. Therefore, this review focuses on antitumor effects curcumin, resveratrol, polydatin cancer. According main databases, only vitro preclinical studies with solid scientific backgrounds reports protective were included. Curcumin, antioxidant, anti‐inflammatory, effects; indeed, they improve efficacy; reduce chemoresistance, angiogenesis, tumor growth; induce apoptosis, autophagy, cell cycle arrest through multiple molecular pathways, including suppression epithelial–mesenchymal transition (EMT), NF‐κB, PI3K/Akt/mTOR, c‐Jun N‐terminal kinase (JNK), MAPK, ERK1/2, STAT signaling pathways; inhibition cyclins matrix metalloproteinase (MMP)‐2 MMP‐9; activation p53 microtubule‐associated protein light chain 3 (LC3).

Язык: Английский

Процитировано

0